Arch Therapeutics, Inc. (OTCMKTS:ARTH) Sees Large Decline in Short Interest

Arch Therapeutics, Inc. (OTCMKTS:ARTH) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 12,400 shares, a decline of 6.1% from the November 15th total of 13,200 shares. Based on an average daily volume of 9,000 shares, the short-interest ratio is presently 1.4 days.

Arch Therapeutics Stock Performance

ARTH stock traded up $0.03 during trading on Monday, hitting $0.25. The company had a trading volume of 1,300 shares, compared to its average volume of 6,544. Arch Therapeutics has a one year low of $0.17 and a one year high of $9.00. The business has a 50-day moving average of $0.27 and a 200-day moving average of $0.59.

About Arch Therapeutics

Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.